| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22006 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | In combination with lenvatinib (Lenvima®) is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation. |
| Assessment Process | |
| Rapid review commissioned | 07/02/2022 |
| Rapid review completed | 04/03/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with lenvatinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/04/2022 |
| Pre-submission consultation with Applicant | 09/05/2022 |
| Full submission received from Applicant | 21/02/2023 |
| Preliminary review sent to Applicant | 03/08/2023 |
| NCPE assessment re-commenced | 05/09/2023 |
| Follow-up to preliminary review sent to Applicant | 19/09/2023 |
| NCPE assessment re-commenced | 06/11/2023 |
| Factual accuracy sent to Applicant | 01/12/2023 |
| NCPE assessment re-commenced | 11/12/2023 |
| NCPE assessment completed | 18/12/2023 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab, in combination with lenvatinib, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.